|
|
News Breaks | | | | September 4, 2012 | | 07:58 EDT |  | ONXX | Onyx Pharmaceuticals price target raised to $86 to $80 at RW Baird
Baird raised its price target on Onyx Pharmaceuticals ahead of the launch of its multiple myeloma drug, Kyprolis. The firm cited bullish survey data including reception and pricing for the drug. Shares are Outperform rated. | |
|
News For ONXX From The Last 14 Days Check below for free stories on ONXX the last two weeks. |
|
|
| May 8, 2013 | | 08:52 EDT | | ONXX | Onyx Pharmaceuticals price target raised to $115 from $105 at Maxim
 Subscribe for More Information | | | May 7, 2013 | | 16:01 EDT |  | ONXX | Onyx Pharmaceuticals reports Q1 EPS (47c), consensus (47c)
Reports Q1 revenue $145.5M, consensus $134.36M. | |
|
|
|
|
|
|
